References
-
1
Veijola L I, Oksanen A M, Sipponen P I et al.
Association of autoimmune type atrophic corpus gastritis with Helicobacter pylori infection.
World J Gastroenterol.
2010;
16
83-88
-
2
Valle J, Kekki M, Sipponen P et al.
Long-term course and consequences of Helicobacter pylori gastritis. Results of 32-years follow-up study.
Scand J Gastroenterol.
1996;
31
546-550
-
3
Claeys D, Faller G, Appermelk B J et al.
The gastric H+, K+-ATPase is a major autoantigen in chronic Helicobacter pylori gastritis with body mucosa atrophy.
Gastroenterology.
1998;
115
340-347
-
4
Wang Y R, Richter J E, Dempsey D T.
Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006.
Ann Surg.
2010;
251
51-58
-
5
Sadic J, Borgstrom A, Manjer J et al.
Bleeding peptic ulcer – time trends in incidence, treatment and mortality in Sweden.
Aliment Pharmacol Ther.
2009;
30
392-398
-
6
Groenen M J, Kuipers E J, Hansen B E et al.
Incidence of duodenal ulcers and gastric ulcers in a Western population: back to where it started.
Can J Gastroenterol.
2009;
23
604-608
-
7
Cai S, Garcia Rodriguez L A, Masso-Gonzalez E L et al.
Uncomplicated peptic ulcer in the UK: trends from 1997 to 2005.
Aliment Pharmacol Ther.
2009;
30
1039-1048
-
8
Asfeldt A M, Steigen S E, Lochen M L et al.
The natural course of Helicobacter pylori infection on endoscopic findings in a population during 17 years of follow-up: the Sorreisa gastrointestinal disorder study.
Eur J Epidemiol.
2009;
24
649-658
-
9
Marshall B J, Warren J R.
Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.
Lancet.
1984;
1
1311-1315
-
10
Axon A T.
Relationship between Helicobacter pylori gastritis, gastric cancer and gastric acid secretion.
Adv Med Sci.
2007;
52
55-60
-
11
Garrow D, Delegge M H.
Risk factors for gastrointestinal ulcer disease in the US population.
Dig Dis Sci.
2010;
55
66-72
-
12
Mabe K, Takahashi M, Oizumi H et al.
Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer?.
World J Gastroenterol.
2009;
15
4290-4297
-
13
Fuccio L, Zagari R M, Minardi M E et al.
Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer.
Aliment Pharmacol Ther.
2007;
25
133-141
-
14
Fukase K, Kato S, Kikuchi S et al.
Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial.
Lancet.
2008;
372
392-397
-
15
Wong B C, Lam S K, Wong W M et al.
Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial.
JAMA.
2004;
291
187-194
-
16
Wu C Y, Kuo K N, Wu M S et al.
Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease.
Gastroenterology.
2009;
137
1641-1648
-
17
Wu C Y, Wu M S, Kuo K N et al.
Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients.
J Clin Oncol.
2010;
28
2952-2957
-
18
Wang W H, Huang J Q, Zheng G F et al.
Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis.
J Natl Cancer Inst.
2003;
95
1784-1791
-
19
Conzales-Perez A, Garcia Rodriguez L A, Lopez-Ridaura R.
Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis.
BMC Cancer.
2003;
3
28-39
-
20
Yanaoka K, Oka M, Yoshimura N et al.
Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion.
Int J Cancer.
2010;
126
1467-1473
H. KashiwagiMD
Department of Surgery
Jikei University School of Medicine
3-25-8, Nishishinbashi
Minato-ku, Tokyo, Japan 105-8461
Fax: +81-3-5472-4120
eMail: hkashiwagi.surg@jikei.ac.jp
